Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat lub rodzic/opiekun prawny dla osób poniżej 18 lat
- •Dla dzieci: wiek od 1 roku do poniżej 18 lat, waga co najmniej 8 kg
- •Diagnoza nowo rozpoznanej białaczki szpikowej (AML) z gorszym rokowaniem
- •Diagnoza zespołu mielodysplastycznego (MDS) wysokiego ryzyka
- •Pacjenci po poprzedniej chemioterapii z nawrotem lub brakiem odpowiedzi na leczenie
- •Rozumienie wymagań badania i podpisanie zgody
- •Dla młodzieży: wiek od 1 roku do 39 lat spełniający kryteria wagowe
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Maro Ohanian
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.